INTERGROWTH-21 Identifies High Prevalence of Low Symphysis–Fundal Height in Indigenous Pregnant Women Experiencing Multiple Infections, Nutrient Deficiencies, and Inflammation: The Maternal Infections, Nutrient Deficiencies, and Inflammation (MINDI) Cohort

Doris González-Fernández,1 Elizabeta Nemeth,2 Emérita del Carmen Pons,3 Delfina Rueda,4 Odalis Teresa Sinisterra,5 Enrique Murillo,6 Veena Sangkhiae,4 Lisa M Starr,7 Marilyn E Scott,7 and Kristine G Koski1

1School of Human Nutrition, McGill University (Macdonald Campus), Ste-Anne-de-Bellevue, Quebec, Canada; 2Center for Iron Disorders, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; 3Department of Nutritional Health, Ministry of Health, Panama City, Panama; 4“Comarca Ngäbe-Buglé” Health Region, Ministry of Health, San Félix, Chiriquí Province, Panama; 5“Panamá Norte” Health Region, Ministry of Health, Panama City, Panama; 6Department of Biochemistry, University of Panama, Panama City, Panama; and 7Institute of Parasitology, McGill University (Macdonald Campus), Ste-Anne-de-Bellevue, Quebec, Canada

ABSTRACT

Background: In the absence of ultrasound, symphysis–fundal height (SFH) can assess maternal–fetal well-being as it is associated with gestational age, fetal weight, and amniotic fluid volume. However, other modifiers of SFH, including maternal infections, nutrient deficiencies, and inflammation (MINDI), have not been widely explored.

Objectives: Our objectives were 2-fold: 1) to assess prevalence of low SFH in indigenous Panamanian women using both Pan-American Health Organization (PAHO) and INTERGROWTH-21 standards and 2) to explore associations of SFH with maternal health indicators: infections (oral, skin, urogenital, nematode infections), nutrient deficiencies [protein and iron indicators (ferritin, serum iron, serum transferrin receptor, hepcidin), folate, and vitamins A, D, and B-12], and inflammation [leukocytes, C-reactive protein (CRP), cytokines].

Methods: For this cross-sectional study, low-SFH-for-gestational-age was assessed using PAHO and INTERGROWTH <10th centile in 174 women at ≥16 weeks of gestation. Bootstrapping selected MINDI variables for inclusion in multivariable fractional polynomial (MFP) logistic regressions for low SFH. Associations of MINDI variables with hepcidin were also investigated.

Results: Prevalence of low SFH was 8% using PAHO, but using INTERGROWTH, 50.6% had SFH <10th centile, including 37.9% <3rd centile. Both PAHO-SFH <10th centile and INTERGROWTH-SFH <3rd centile were associated with higher hepcidin (OR = 1.12, P = 0.008, and OR = 3.04, P = 0.001, respectively) and with lower TNF-α (OR = 0.73, P = 0.012, and OR = 0.93, P = 0.015, respectively). Wood-smoke exposure increased the odds of PAHO-SFH <10th centile (OR = 1.19, P = 0.009), whereas higher BMI decreased the odds of INTERGROWTH-SFH <3rd centile (OR = 0.87, P = 0.012). Lower pulse pressure (OR = 0.90, P = 0.009) and lower inflammatory responses [lower lymphocytes (OR = 0.21, P = 0.026), IL-17 (OR = 0.89, P = 0.01)) distinguished SFH <3rd centile from SFH ≥3rd to <10th centiles using INTERGROWTH-21 standards. The MFP regression for hepcidin controlling for SFH (adjusted R² = 0.40, P = 0.001) revealed associations with indicators of inflammation (CRP, P < 0.0001; IL-17, P = 0.012), acidic urinary pH (P = 0.008), and higher intake of supplements (P = 0.035).

Conclusions: Associations of low SFH with MINDI variables, including hepcidin, highlight its potential for early detection of multicausal in utero growth faltering. Curr Dev Nutr 2021;5:nzab012

Keywords: indigenous pregnant women, symphysis–fundal height, INTERGROWTH-21 standards, inflammation, protein malnutrition, hepcidin

© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Manuscript received September 3, 2020; initial review completed January 20, 2021; revision accepted February 17, 2021. Published online April 12, 2021. Supported by the “Secretaría Nacional de Ciencia, Tecnología e Innovación” (SENACYT) Panama (COL08-009) (EM, MES, KGK), the McGill Vitamin Fund (MES, KGK), and the NIH (EM, KGK). Author disclosures: The authors report no conflicts of interest. Supplemental Tables 1–3 are available from the “Supplementary data” link in the online posting of the article and from the same link in the online table of contents at https://academic.oup.com/cdn/.
**Introduction**

Clinically measured symphysis–fundal height (SFH) is the first-level screening tool often used for assessing fetal size in marginalized communities in the absence of ultrasound (1). This simple biomarker uses a tape measure in complete contact with the maternal abdomen skin midline to measure the distance between the symphysis pubis and the upper height of the uterine fundus (2). SFH has been strongly correlated with fetal weight and with amniotic fluid volume (3). Public health interest has focused on using SFH as an indicator of small-for-gestational-age (SGA), defined as birth weight <10th centile (4), although a limitation of these previous studies has been the small number of fetuses with growth <10th centile (5).

Presently, SFH is part of the routine pregnancy assessment according to the National Guidelines from the United Kingdom, the United States, Canada, and Ireland (6). In Latin America, the Pan American Health Organization (PAHO) includes SFH standards as part of the recommended routine antenatal care (7). These PAHO guidelines, developed in 1984 by the Latin American Center of Perinatology/Women and Reproductive Health (CLAP/WR) in Montevideo (Uruguay), were based on 1074 SFH measurements during the follow-up of 47 normal pregnant women (white race, medium socioeconomic class, and good nutritional state) (8); they reported a sensitivity of SFH of 52% and a specificity of 92% in the detection of intrauterine growth restriction (7).

Current WHO recommendations state that a normal SFH “may be a reasonable indicator of a healthy baby” (9). However, one of the main concerns for the use of SFH had been the lack of international standardization (10, 11). To address this, the INTERGROWTH-21 project targeted the development of new international SFH standards using a large cohort of 4607 healthy pregnant women from Brazil, China, India, Italy, Kenya, Oman, the United Kingdom, and the United States (12), but comparative studies applying these new standards are scarce.

To date, SFH has been used in low- and middle-income countries for estimating gestational age (GA), guiding clinical decisions in pregnant women treated for *Plasmodium falciparum* malaria (13), and in HIV-infected women for timing the initiation of antiretroviral treatment (14, 15). Lower SFH has been associated with HIV-positive women whose fetuses were infected with HIV (16) and with lower SFH in mothers with severe anemia compared with nonanemic women (17). SFH has also been used for the detection of multiple gestations (18) and for identifying low (oligohydramnios) or high (polyhydramnios) amniotic fluid volume (3). Recently, the intake of iron supplements, higher hemoglobin, and higher diastolic blood pressure were associated with higher SFH z scores calculated using INTERGROWTH standards in a Colombian population of mixed ethnic backgrounds (19). However, associations of SFH with other clinical indicators of maternal health have not been investigated.

In Panama, both maternal and infant mortality are highest in indigenous communities, where 36% of infant mortality is due to perinatal causes (20). At the time of this study in 2010, maternal mortality rates in the Ngäbe-Buglé comarca were as high as 200 per 1000 live births (21) and the prevalence of low birth weight in the country was 8.8% (22) but suspected of being higher in the Ngäbe-Buglé indigenous community as 56% of mothers did not have professional delivery attendants (22). We had previously reported in pregnant Ngäbe-Buglé women a high prevalence of maternal infections (23), inflammation, and multiple nutrient deficiencies (24) and an association of low SFH with low maternal pulse pressure (25).

For this cross-sectional study, we applied PAHO’s CLAP/WR and the more recent international INTERGROWTH-21 standards to identify the prevalence of low SFH in the Ngäbe-Buglé community. We also explored if co-existing maternal infections, nutrient deficiencies, and inflammation (MINDI) were associated with low SFH using both PAHO-CLAP/WR and INTERGROWTH-21 standards (henceforth, CLAP and INTERGROWTH).

**Methods**

**Design**

For this cross-sectional study, we recruited pregnant women from the Ngäbe-Buglé indigenous community in the province of Chiriquí Panama from August to December 2010 during their routine pregnancy follow-up. We used 2 approaches to identify low SFH. First, as recommended by the Panamanian Ministry of Health at the time of the study (26), we compared our population with CLAP standards (7) and classified women into 3 groups: SFH <10th, ≥10th to ≤90th centiles (SFH 10–90), and >90th centile for GA. Second, INTERGROWTH allowed us to classify women into 4 groups: <3rd centile, ≥3rd to <10th centiles (SFH 3–10), SFH 10–90, and >90th centile for GA. Comparisons of MINDI variables that differed among these SFH classifications were identified as well as MINDI variables associated with 1) increasing the odds of SFH <10th and SFH >90th centile [compared with normal SFH (SFH 10–90) using CLAP standards] and with 2) increasing the odds of SFH <3rd, SFH 3–10, or SFH >90th centile compared with SFH 10–90 using INTERGROWTH standards. MINDI variables specifically associated with the odds of SFH <3rd centile compared with SFH 3–10 were also identified.

**Ethics**

Ethics approval was obtained from the Gorgas Memorial Institute in Panama (no. 1618/CNBI/ICGES/10), which required as a prerequisite for final approval a signed agreement with indigenous authorities of the Ngäbe-Buglé comarca and with the Panamanian Ministry of Health. Ethics approval was also obtained from McGill University in Canada (no. A03-M16-10A). All were in accordance with the recommendations of the Operational Guides of Bioethics in Research. Participants gave written informed consent in accordance with the Declaration of Helsinki (27).

**Recruitment**

Nurses working at 14 health centers of the Ngäbe-Buglé informed the community of the visit of the research team during the scheduled “pregnancy follow-up day” as most women lived within 2 h walking distance from community health centers. All pregnant women attending these routine check-ups were invited to participate. As an incentive for health promotion from the Panamanian Ministry of Health, all indigenous pregnant women attending prenatal follow-up received food vouchers, and through participation in the project, they were provided with an additional laboratory evaluation without needing to travel to the regional hospital, at a distance of 1–3 h by car. Based on the annual estimate of 2127 live births in the Ngäbe-Buglé community in 2010 (28), we...
recruited > 90% of the pregnant women in the region at the time of the study. Although we had determined that a sample of 92 pregnant women was required to detect an SGA birth with a level of confidence of 95% based on a prevalence of 6.7% for low birth weight reported by the Panamanian Ministry of Health (28), we were able to recruit 213 pregnant women, where 174 were ≥ 16 weeks’ GA based on last menstrual period, the minimal GA required for assessing SFH using international INTERGROWTH standards (12). Of note, malaria was not endemic and, in all participants, HIV was ruled out by the Ministry of Health and gestational diabetes was ruled out by the absence of glucosuria.

**Questionnaire**

Participants answered questions about date of last menstrual period and parity, time in months, and dosage of iron supplementation (60-mg tablets) or a standard multiple nutrient supplement [MNS; tablespoon (tbsp)/d] containing the following in every 100 g (6 tbsp): energy (400 kcal), protein (12.0 g), lipids (12–14 g), vitamin A (250 μg), vitamin E (10 mg), vitamin B-1 (0.50 mg), vitamin B-2 (0.50 mg), vitamin B-3 (6.0 mg), vitamin B-6 (0.50 mg), vitamin B-12 (0.90 μg), folic acid (85 μg), iron (4.0 mg iron bisglycinate), zinc (4.5 mg amino chelated), calcium (100 mg), phosphorus (55 mg), and copper (400 μg). Mothers also reported wood-smoke and fieldwork exposure (hours per day), as well as the number of portions of animal-source foods, leafy vegetables, yellow/red fruits, and vegetables per week, in order to evaluate possible low intake of the nutrients (protein, iron, vitamin B-12, folic acid, and vitamin A) that might be associated with the high prevalence of anemia and malnutrition in the population (29).

**Physical examination**

**Maternal anthropometry.**

Prepregnancy weights were not available; therefore, BMI at interview was calculated as maternal weight/height squared. Current maternal weight that included the maternal–fetal unit was also used to classify women as underweight, normal weight, or overweight by comparing it with the reference weight for a determined height and GA according to CLAP (26, 30) and used as the standard according to PAHO guidelines (31).

**Symphysis–fundal height.**

SFH was measured using a nonelastic tape from the pubic symphysis to the highest point of the uterine fundus while the mother was in a supine position after emptying her bladder. Initially, the tape was placed at the upper border of the symphysis pubis straightened over the uterus until reaching the fundus; measurements were recorded to the nearest complete half centimeter. GA was calculated using the days of amenorrhea according to last menstrual period. The Panamanian guidelines for pregnancy follow-up provide a table with percentiles 10 and 90 of SFH for GA from the 13th to 40th week (26) based on CLAP (7), and this was used to classify women as <10th, ≥10th to <90th, and ≥90th centiles. Also, the SFH calculators developed by the INTERGROWTH-21 Network were used to calculate centiles of SFH for GA expressed in completed weeksof gestation using data ≥16 weeks of gestation and excluding SFH values <12 cm or >38 cm, given that SFH is not clinically accepted beyond these limits (12). Continuous INTERGROWTH centiles for GA were further classified into 4 categories: <3rd, 3–10, 10–90, and >90th centiles. Data from women with GA ≥16 wk were used for analyses for both CLAP and INTERGROWTH standards.

**Blood pressure and plasma volume calculations.**

Maternal blood pressure (Omron HEM-790IT automatic BP monitor; IntelliSense®) was measured in a sitting position and considered high if systolic (SBP) ≥140 mm Hg or diastolic (DBP) ≥90 mm Hg and low if SBP <100 and DBP <60 mm Hg (32). Mean arterial pressure (MAP) was calculated as DBP + 1/3 (SBP − DBP) (33) and MAP was considered elevated if >87 mm Hg (10–18 wk), >84 mm Hg (18–34 wk), and >86 mm Hg (>34 wk) (34). Pulse pressure was calculated as the difference between SBP and DBP (35).

For the calculation of plasma volume, we first used Nadler’s equation to calculate the total blood volume [TVB = 0.3561 × (height in meters)³ + 0.03308 × weight in kilograms + 0.1833] (36). Plasma volume was calculated as TVB × (1 − hematocrit) (37). A low plasma volume was considered if <2 L in the first trimester, <2.6 L in the second trimester, and <2.8 L in the third trimester, according to values less than the fifth centile reported by de Haas et al. (38).

**Infections**

Maternal infections were evaluated both clinically and using laboratory measurements as previously described (23). Briefly, caries and skin lesions compatible with scabies were detected during the clinical exam (yes/no). Urinary infection was assessed and scored using microscopic analysis of centrifuged urine. Urine sediment was used for assessing semiquantitative scores (0–4) for urinary bacteria and vaginal Gram stains for semiquantitative scores of *Lactobacillus*, *Bacteroides/Gardnerella*, and *Mobiluncus* to diagnose bacterial vaginosis (Nugent score ≥7) (39). Similarly, scores for vaginal trichomoniasis and diplodococcal infection were assessed. Vaginal yeast was detected and scored by direct vaginal smears. The presence of intestinal nematodes (*Ascaris*, hookworm, and *Trichuris*) was identified in the 101 women who provided stool samples using direct microscopic fecal examination and Kato-Katz and Flotac tests as previously described (23).

**Laboratory analyses**

For the evaluation of hematological status and inflammation, complete RBC and white blood cell (WBC) counts (BC-5500 Mindray Auto Hematology Analyzer; Mindray (UK) Ltd) were performed. Anemia was defined as hemoglobin <110 g/L (40). Eosinophilia, a proxy for intestinal nematode infection, was defined as eosinophil count >0.6 × 10⁹/mm³ (41).

Serum was analyzed for C-reactive protein (CRP) using solid-phase ELISA (MP Biomedicals) with a minimum detectable concentration of 0.95 nmol/L and for cytokines IL-1β, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-γ, TNF-α, and monocyte chemotactic protein 1 (MCP-1) that were quantified via Luminex using a Human Cytokine/Chemokine Magnetic Bead Panel (Millipore Corporation Canada).

Maternal iron status was evaluated based on serum iron (spectrophotometry, FERENE-ENDPOINT, IRON-SL kit; Sekisui Diagnostics), ferritin (ELISA; MP Biomedicals), and serum transferrin receptor (sTfR; RAMCO immunoassay; RAMCO Laboratories). Other serum nutrients evaluated were as follows: 1) folic acid and vitamin B-12 concentrations using immunoauto-chemiluminescence
(MODULAR E170; Roche Diagnostics); 2) 25-hydroxyvitamin D using the LIAISON®; DiaSorin, direct competitive chemiluminescence immunoassay; 3) vitamin A using HPLC (42); and 4) retinol-binding protein (RBPI) using Human RBP4 ELISA (MP Biomedical) with a standard curve range between 0.14 and 100 ng/mL. Hepcidin was measured using an Intrinsic Hepcidin IX ELISA kit (Intrinsic LifeSciences).

Cutoffs for iron status indicators were set as serum iron < 8.9 µmol/L, ferritin < 20 µg/L (40), or elevated sTfR (> 8.3 mg/L) (RAMCO Laboratories, INC). Folic acid deficiency was defined as < 10 nmol/L and vitamin B-12 deficiency as < 150 pmol/L (43). We used a cutoff for vitamin D deficiency of < 50 nmol/L (44). The cutoff for low vitamin A was set at < 1.05 µmol/L (45) and low protein status was defined as RBP < 30 mg/L (46), which is considered a sensitive indicator of protein status even before clinical signs of malnutrition appear (47).

Urine samples were assessed using URISCAN strips (YD Diagnostics) on a Miditron-M semiautomated reflectance photometer (Roche) for semiquantitative measurement of leukocyte esterase (positive reaction considered as urinary tract infection (48)), urinary-specific gravity (considered hypohydration if > 1.020) (49), and urinary pH as a general indicator of the acid–base balance (50) and of volemic status given its positive correlation with extracellular volume (51).

Statistical analysis
All statistical analyses were performed using STATA 16 (StataCorp). Differences in maternal characteristics and nutritional, inflammation, and infection status were assessed among women having SFH < 10th, ≥ 10th to ≤ 90th, and > 90th centiles (CLAP) and SFH < 3rd, SFH 3–10, SFH 10–90, and > 90th centiles (INTERGROWTH). One-factor ANOVA or Kruskal-Wallis analyses were used depending on the nature of continuous variables. Frequency comparisons of discrete variables were made among classifications using chi-square or Fisher’s exact tests. We report P values at < 0.05 and at the Bonferroni-corrected P value calculated for each group of these analyses. We also compared the continuous variable for SFH centiles for GA, inflammation, and iron status indicators by the presence/absence of protein deficiency, indicated by RBP < 30 mg/L, using Kruskal-Wallis tests.

Selection of independent variables and modeling strategy
We began by grouping independent variables as follows: 1) maternal characteristics (GA, maternal age, parity, BMI, exposure to wood smoke and fieldwork), 2) supplementation and diet (months on iron supplements, MNS tsp/d, weekly portions of animal-source foods, and yellow/red and green-leafy fruits and vegetables), 3) blood cell counts and differentials (WBCs, RBCs, and platelets), 4) cytokines (IL-1β, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17, TNF-α, INF-γ, MCP-1), 5) serum nutritional indicators (RBPI, folic acid, and vitamins A, B-12, and D), 6) iron status indicators (ferritin, sTfR, serum iron, hepcidin), 7) vaginal micro-organisms (Lactobacillus, Bacteroides/Gardnerella, Mobiluncus, Trichomonas, yeast, Diplococcus), 8) urinary indicators (urinary pH, specific gravity, bacteria, leukocytes, crystals), and 9) other infections (caries, scabies). The subsample of women with data on intestinal nematodes (Ascaris, hookworm, Trichuris) was tested separately.

We selected variables from each of the above-described groups using a bootstrap procedure. The nonparametric bootstrap procedure resamples observations with replacements, drawing repeated bootstrap samples from the original dataset (52). We applied a backward stepwise algorithm to count the total number of times variables from each group were selected after 1000 repetitions, and preliminary candidate variables entering ≥ 500 times (50%) (53) were used to run multivariate fractional polynomial (MFP) logistic regression models.

MFP modeling approach
Preparative analyses had shown nonlinear associations between our biological measurements and outcome variables. To address the issue of nonlinearity, we used an MFP algorithm for assessing associations of our MINDI variables with low and high SFH. The MFP compares functional fractional polynomial transformations of predictor variables and selects the most robust ones by determination of suitable forms of continuous independent variables while correcting nonlinear associations (54). The final MFP backwards selection of variables was set at P < 0.25 to avoid missing variables of possible importance (55). SFH centile variables already adjust for GA, but given the variation in independent variables during pregnancy and the variation in the interpretation of SFH for the detection of SGA depending on GA (56), models were controlled by trimester. Postestimation graphs describing the odds of low SFH with significantly associated nutritional and inflammation biomarkers were drawn. We followed a similar procedure to run an MFP linear regression model for log-hepcidin as a dependent variable while controlling for GA in weeks and for SFH in centimeters. For all models, absence of collinearity and instability of regression coefficients were evaluated using a variance inflation factor (VIF) < 10 and a condition number < 30, respectively. Little’s chi-square test was used when intestinal parasites were included to evaluate randomness of missing data (57).

Results
Population characteristics
Maternal characteristics are described in Table 1. Women had a median length of gestation of 30 wk (range: 16.3–42 wk) and 37.4% were in their second and 62.6% were in their third trimester. The majority (63.8%) had normal weight, 24.1% had high weight, and 12.1% had low weight for GA by PAHO standards. Adolescent pregnancies (≤ 19 y, 26.4%) and multiparity (≥ 5 pregnancies, 33.3%) were present. Most women (92%) were exposed to wood smoke used for cooking (median = 2 h/d; range: 0–6 h/d) and 51.6% did fieldwork (median: 1 h/d; range: 0–10 h/d). Although hypertension using SBP and DBP was not found, hypotension (blood pressure < 100/60 mm Hg) occurred in 24% and elevated MAP by GA in 12.6%. Plasma volume was low for GA in 99.4% of pregnancies, and urinary-specific gravity > 1.020, indicating hypohydration, occurred in 25.4%.

Table 1 also shows the presence of multiple infections, nutrient deficiencies, and inflammation in our MINDI cohort. Infections were highly prevalent; 96.0% had ≥ 2 co-occurring infections, including bacterial, protozoal, fungal, or nematode infections. Although, in general, WBC indices were within normal limits, we found eosinophilia, which is commonly associated with nematode infections, in 14.9% and elevated CRP in 12.1%.
### TABLE 1 Maternal characteristics of indigenous Ngäbe-Buglé pregnant women

| Characteristic                                      | Values                                      |
|-----------------------------------------------------|---------------------------------------------|
| **General characteristics**                         |                                             |
| Age, y                                              | 24 (13–45)                                  |
| Parity, n                                           | 3 (1–12)                                    |
| Gestational age, wk                                 | 30.8 (16.3–42)                              |
| Unadjusted BMI, kg/m²                                | 24.8 (17.1–35.8)                            |
| Underweight, %                                      | 12.1                                        |
| Normal weight, %                                     | 63.8                                        |
| Overweight, %                                       | 24.1                                        |
| Fieldwork, h/d                                      | 1 (0–10)                                    |
| Wood-smoke exposure, h/d                            | 2 (0–6)                                     |
| **Foods, <7 servings/wk, %**                        |                                             |
| Animal-source foods                                 | 81.0                                        |
| Yellow/red fruits and vegetables                    | 91.5                                        |
| Green-leafy vegetables                              | 89.1                                        |
| **Supplementation**                                 |                                             |
| Taking iron supplements, %                          | 85.6                                        |
| Months on iron supplements                          | 2 (0–10)                                    |
| Taking MNS supplements, %                           | 56.3                                        |
| MNS, tbsp/d                                         | 1 (0–9)                                     |
| **Infections, %**                                   |                                             |
| Carios                                              | 19.5                                        |
| Scabies                                             | 19.0                                        |
| UTI (n = 169)                                       | 63.9                                        |
| Ascaris (n = 101)                                   | 32.7                                        |
| Hookworm (n = 101)                                  | 59.4                                        |
| Trichuris (n = 101)                                 | 13.9                                        |
| **Vaginal microflora (n = 173), %**                 |                                             |
| Lactobacillus                                       | 53.8                                        |
| Bacteroides/Gardnerella                             | 93.1                                        |
| Mobiluncus                                          | 84.4                                        |
| Trichomonas                                         | 76.3                                        |
| Yeast                                               | 23.6                                        |
| Diplococcus                                         | 21.4                                        |
| **Inflammation indicators**                         |                                             |
| CRP, mg/L                                           | 3.6 (1.5–6.7)                               |
| Elevated CRP, %                                     | 12.1                                        |
| Cytokines, median (IQR), pg/mL                      |                                             |
| IL-1β                                               | 1.8 (0.5–8.4)                               |
| IL-4                                                | 5.0 (2.3–19.2)                              |
| IL-6                                                | 1.6 (1.6–13.1)                              |
| IL-10                                               | 1.6 (0.1–4.8)                               |
| IL-12                                               | 1.8 (0.03–25.9)                             |
| IL-13                                               | 1.6 (0.1–7.4)                               |
| IL-17                                               | 2.2 (0.1–10.8)                              |
| TNF-α                                               | 6.7 (0.02–12.4)                             |
| IFN-γ                                               | 3.6 (1.0–13.4)                              |
| MCP-1                                               | 175 (115–274)                               |
| **Blood pressure, median (IQR), mm Hg**             |                                             |
| Systolic                                            | 102 (96–110)                                |
| Diastolic                                           | 60 (56–68)                                  |
| Low blood pressure, %                               | 24.1                                        |
| MAP, median (IQR)                                   | 74.3 (70.0–81.3)                            |
| Elevated MAP, %                                     | 12.6                                        |
| Pulse pressure                                      | 40 (35–47)                                  |
| **Other perfusion indicators**                      |                                             |
| Plasma volume, ml                                   | 2106 (1733–2621)                            |
| Low plasma volume                                   | 99.4                                        |
| Uninary-specific gravity                            | 1.020 (1.005–1.030)                         |
| Uninary-specific gravity >1.020, %                  | 25.4                                        |
| Uninary pH                                          | 6 (5–8)                                     |

### TABLE 1 (Continued)

| Nutritional status indicators                        | Values                                      |
|-----------------------------------------------------|---------------------------------------------|
| Ferritin, μg/L                                      | 9.9 (5.5–20.4)                              |
| Ferritin <20 μg/L, %                                | 73.6                                        |
| sTfR, mg/L                                          | 5.3 (3.9–7.3)                               |
| sTfR >8.3 mg/L, %                                   | 18.4                                        |
| Serum iron, μmol/L                                 | 8.4 (5.4–13.6)                              |
| Serum iron <8.9 μmol/L, %                           | 53.4                                        |
| Folic acid, nmol/L                                 | 13.3 (9.8–18.2)                             |
| Folic acid <10 nmol/L, %                            | 26.4                                        |
| Vitamin B-12, pmol/L                               | 95.5 (79.0–120.0)                           |
| Vitamin B-12 <150 pmol/L, %                         | 89.1                                        |
| Vitamin D, nmol/L                                  | 45.1 (33.5–56.2)                            |
| Vitamin D <50 nmol/L, %                            | 62.6                                        |
| Vitamin A, μmol/L                                  | 1.1 (0.9–1.4)                               |
| Vitamin A <1.05 μmol/L, %                           | 41.9                                        |
| RBP                                                 | 44.1 (28.3–84.0)                            |
| RBP <30 mg/L, %                                     | 28.9                                        |
| Hecpicin, μg/L                                      | 7.4 (5.0–11.3)                              |
| **Blood cell counts**                               |                                             |
| RBCs, ×10[12]/mm³                                   | 3.71 (3.5–3.9)                              |
| Hemoglobin, g/L                                     | 112 (104.0–118.0)                           |
| Anemia, %                                           | 37.9                                        |
| Hematocrit, %                                       | 34.9 (33.1–36.6)                            |
| MCV, fl                                             | 94.6 (91.2–98.0)                            |
| MCH, pg                                             | 30.3 (29.1–31.4)                            |
| MCHC, g/L                                           | 319.0 (311.0–326.0)                         |
| RDW-CV, %                                           | 13.4 (13.1–13.7)                            |
| Platelets, ×10[12]/mm³                              | 255.5 (73–445)                              |
| Total WBCs, ×10[9]/mm³                              | 8.5 (7.2–9.8)                               |
| Neutrophils                                         | 5.9 (4.6–6.8)                               |
| Lymphocytes                                         | 1.9 (1.7–2.3)                               |
| Monocytes                                           | 0.4 (0.3–0.4)                               |
| Eosinophils                                         | 0.3 (0.2–0.5)                               |
| Eosinophils >0.6, %                                 | 14.9                                        |
| Basophils                                           | 0.03 (0.02–0.04)                            |

1Values are medians (range) unless otherwise indicated. CRP, C-reactive protein; MAP, mean arterial pressure; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCP-1, monocyte chemotactic protein 1; MCV, mean corpuscular volume; MNS multiple nutrient supplement; RBP, retinol-binding protein; RDW-CV, red blood cell distribution width; sTfR, serum transferrin receptor; tbsp, tablespoons; UTI, urinary tract infection (detected by positive urinary leukocyte esterase); WBC, white blood cell.

2Elevated CRP: >3 mg/L in the first, >20.3 mg/L in the second, and >8.1 mg/L in the third trimester (41).

3Low blood pressure: <100/60 mm Hg (35).

4Elevated MAP: >87 mm Hg (10–18 wk), >84 mm Hg (18–34 wk), and >86 mm Hg (>34 wk) (34).

5Low plasma volume: <2 L in the first, <2.6 L in the second, and <2.8 L in the third trimester (38).

6Values are medians (IQR) unless otherwise noted.

Diet quality was suboptimal. Women had low weekly intakes of animal-source foods (median = 2 portions/wk; range: 0–14 portions/wk), green-leafy vegetables (median = 1 portion/wk; range: 0–8 portions/wk), and yellow/red fruits and vegetables (median = 1 portion/wk; range: 0–14 portions/wk). Iron tablets (elemental iron, 60 mg) had been taken for a median of 2 mo (range: 0–10 mo), and women consumed 1 tbsp/d of MNS (median: 1; range: 0–9 tbsp/d) out of the recommended 6 tbsp/d. Despite availability of supplements, 38% had anemia, 73.6% had low ferritin, and 53.4% had low serum iron, but only
18.4% had elevated sTfR. Median hepcidin concentration was 7.38 μg/L (range: 0.30–40.49 μg/L). Multiple micronutrient deficiencies [vitamin B-12 (89.1%), vitamin D (62.6%), vitamin A (41.9%), and folic acid (26.4%)] were present.

**Prevalence of low SFH by CLAP and INTERGROWTH standards**

Scatterplots of SFH for GA with fitted lines showing the 10th and 90th centiles according to CLAP and INTERGROWTH standards are shown in Figure 1A and B, respectively.

The prevalence of SFH <10th centile was 8.0% and that of SFH >90th centile was 28.7% using CLAP. In contrast, when using INTERGROWTH, the prevalence of SFH <3rd centile was 37.9%, 12.6% were classified as SFH 3–10, 40.2% had SFH 10–90, and 9.2% had SFH >90th centile.

**Differences in MINDI variables among SFH classifications**

Comparisons among SFH <10th, between the 10th and the 90th, and >90th centiles using CLAP are summarized in Supplemental Table 1. Using CLAP, few variables showed differences at P < 0.05: mothers with SFH <10th centile had more acidic urine (P = 0.015), higher hepcidin (P = 0.044), lower TNF-α (P = 0.007), lower IL-1β (P = 0.014), and lower than expected vitamin D deficiency (P = 0.013). Using a Bonferroni-corrected P < 0.001, only underweight was found more often than expected in women with SFH <10th centile when compared with SFH ≥10th centile (P < 0.0001).

Comparisons among SFH <3rd, 3–10, 10–90, and >90th centiles using INTERGROWTH are shown in Supplemental Table 2. More variables differed at P < 0.05 across the INTERGROWTH SFH classification: urinary pH was lower in women with SFH <3rd centile (P = 0.040) and maternal BMI was lower in women with SFH <3rd centile (P = 0.006). We also observed a trend of women with SFH <3rd centile to have lower pulse pressure (P = 0.052). Despite a similar prevalence of individual infections, WBC total count, and differential and CRP concentrations, some cytokines differed across SFH classifications. Women with SFH 3–10 had higher concentrations of IL-6 (P = 0.025) and IL-17 (P = 0.024) compared with those with SFH <3rd and SFH 10–90. They also had higher IL-12 (P = 0.018) and TNF-α (P = 0.010) compared with mothers with SFH <3rd centile. On the other hand, IL-4 was lower in the SFH <3rd centile compared with SFH >90th centile (P = 0.045). With regard to nutritional indicators, RBP concentrations were lower in the SFH <3rd centile compared with the >90th centile (P = 0.017) and protein deficiency (RBP <30 mg/L) was higher than expected in the SFH <3rd centile (P = 0.048); however, vitamin B-12 concentrations were higher in the SFH <3rd centile when compared with SFH 10–90 (P = 0.042). Finally, mothers with an SFH >90th centile had an earlier GA compared with those <10th centile and were less frequently exposed to wood smoke. However, using a Bonferroni-corrected P < 0.001, no variables differed.

**Protein deficiency (RBP ≤30 mg/L) and biomarkers of inflammation and iron status**

Binary comparisons of SFH centiles (continuous variable) and indicators of inflammation and iron status by presence/absence of protein deficiency are shown in Table 2. Using the Bonferroni-corrected P < 0.002 for significance, protein-deficient women had lower basophil counts (P = 0.0003) and higher IL-13 concentrations (P = 0.0009) than protein-sufficient women. At P < 0.05, the SFH centile for GA was lower in protein-deficient women (P = 0.029), who also had a lower eosinophil count (P = 0.032) and lower concentrations of IL-4 (P = 0.005) but higher IL-10 (P = 0.006). CRP, hepcidin, or iron status indicators did not differ by protein status.

**MFP logistic regression models for SFH classifications**

*Model for low SFH according to CLAP.*

As shown in Table 3, higher hepcidin concentrations as well as increased hours per day of wood-smoke exposure were associated with increased odds of an SFH <10th centile compared with an SFH between the 10th and 90th centiles. However, higher TNF-α concentrations...
TABLE 2  Binary comparisons by RBP < 30 mg/L (protein deficient) or RBP ≥ 30 mg/L (protein sufficient) of SFH centiles for GA and inflammation and iron status indicators in 174 indigenous pregnant women

| SFH centile for GA | RBP < 30 mg/L | RBP ≥ 30 mg/L | P |
|-------------------|---------------|---------------|---|
| White blood cells, ×10³/mm³ | 3.0 (0.1–30.3) | 10.3 (0.9–52.5) | 0.029 |
| Neutrophils | 8.2 (7.3–9.8) | 8.5 (7.0–9.9) | 0.621 |
| Lymphocytes | 5.6 (4.7–6.9) | 5.9 (4.6–6.7) | 0.907 |
| Monocytes | 1.9 (1.7–2.2) | 1.9 (1.7–2.3) | 0.386 |
| Eosinophils | 0.3 (0.3–0.4) | 0.4 (0.3–0.4) | 0.648 |
| Basophils | 0.2 (0.2–0.4) | 0.4 (0.2–0.5) | 0.032 |
| Cytokines, pg/mL |
| IL-1β | 2.5 (0.1–9.8) | 1.6 (0.6–7.0) | 0.936 |
| IL-4 | 3.2 (0.7–10.7) | 9.1 (3.2–22.7) | 0.0049 |
| IL-6 | 1.6 (0.5–9.9) | 1.6 (1.6–13.8) | 0.307 |
| IL-10 | 1.6 (1.0–5.9) | 1.0 (0.06–3.9) | 0.066 |
| IL-12 | 0.6 (0.02–28.7) | 1.9 (0.06–21.0) | 0.704 |
| IL-13 | 1.6 (1.6–9.0) | 1.0 (0.08–7.2) | 0.0009 |
| IL-17 | 4.5 (0.1–13.5) | 2.1 (0.1–10.0) | 0.321 |
| IFN-γ | 5.6 (0.02–12.3) | 6.7 (0.02–12.7) | 0.882 |
| CRP, mg/L | 4.3 (2.0–6.7) | 3.2 (1.5–6.7) | 0.583 |
| Hepcidin, μg/L | 7.0 (5.5–12.2) | 7.7 (5.0–10.9) | 0.949 |
| Ferritin, μg/L | 8.7 (5.3–19.3) | 11.4 (5.5–23.7) | 0.392 |
| Serum iron, μmol/L | 8.2 (6.0–13.5) | 8.7 (5.4–14.1) | 0.989 |
| sTfR, mg/L | 6.1 (3.9–7.9) | 5.0 (3.9–6.8) | 0.176 |

1Values are medians (IQR). One-factor ANOVA was used when the variable was normally distributed (total white blood cells, neutrophils, lymphocytes and basophils), and Kruskal-Wallis tests were used for non-normally distributed variables. CRP, C-reactive protein; GA, gestational age; RBP, retinol-binding protein; SFH, symphysis–fundal height; sTfR, serum transferrin receptor.

Models for low SFH according to INTERGROWTH.

An SFH <3rd centile yielded significant associations with MINDI in 3 different models. First, Table 4A shows associations of an SFH <3rd centile compared with SFH 10–90, where 3 main associations of SFH <3rd centile emerged, 2 of them in common with the CLAP SFH <10th centile. Higher hepcidin was associated with increased odds, whereas higher maternal BMI and TNF-α were associated with decreased odds of an SFH <3rd centile. Model associations controlling for covariates are shown in postestimation regression lines (Figure 2B).

In a second model for the subsample of women with data on intestinal nematodes (Supplemental Table 3), the association between an SFH <3rd centile and hepcidin remained and the presence of Trichuris was associated with 5.5 ± 4.8 (P = 0.049) increased odds of an SFH <3rd centile.

In a third model, we compared an SFH <3rd centile with SFH 3–10 (Table 4B). Higher pulse pressure and an increased inflammatory response indicated by higher lymphocyte count and higher concentrations of IL-17 and the chemokine MCP-1 were associated with decreased odds of an SFH <3rd centile when compared with SFH 3–10. Regression lines of associations between an SFH decreased the odds. Regression lines showing the odds of an SFH <10th centile with higher hepcidin, TNF-α, and wood smoke, controlling for model covariates, are shown in Figure 2A.

TABLE 3  MFP logistic regression model for SFH <10th centile compared with SFH between the 10th and 90th centiles using CLAP standards

| Trimester (0 = second, 1 = third trimester) | OR ± SE | P | 95% CI in X | Change in odds for SD increase | Overall model |
|-------------------------------------------|---------|---|-------------|-------------------------------|--------------|
| t Wood smoke, h/d | 0.72 ± 0.56 | 0.675 | 0.16, 3.33 | 0.85 | P < 0.0001, pseudo-R² = 0.383 |
| t TNF-α, pg/mL | 1.99 ± 0.52 | 0.009 | 1.19, 3.34 | 2.79 |
| t Urinary pH | 0.73 ± 0.09 | 0.012 | 0.57, 0.93 | 0.08 |
| t Heparin, μg/L | 0.48 ± 0.20 | 0.087 | 0.20, 1.11 | 0.52 |
| Constant | 1.12 ± 0.05 | 0.008 | 1.03, 1.22 | 2.27 |

1Variables that entered ≥500 bootstrap repetitions but were taken out by the MFP process: multiple nutrient supplement (tbsp/d). The MFP process provided the following equations for transforming covariates (t):

Wood smoke (h/d) = wood smoke − 2.5; TNF-α (pg/mL) = TNF-α − 7.433294524; urinary pH = urinary pH − 6.423728814; hepcidin (μg/L) = hepcidin − 9.676559332. Model VIF: 1.05; condition number: 2.74, n = 118. VIF: variance inflation factor as measurement of collinearity. Values <10 were accepted. Condition numbers <30 were accepted as measurement of stability of coefficients. CLAP, Latin American Center of Perinatology; MFP, multivariable fractional polynomial; SFH, symphysis–fundal height; tbsp, tablespoons.
<3rd centile with pulse pressure, lymphocytes, IL-17, and MCP-1 are shown in Figure 3.

The MFP model comparing SFH 3–10 with normal SFH (10–90) is shown in Table 4C. Older maternal age in years was associated with decreased odds of SFH 3–10, whereas higher IL-12 and higher ferritin were associated with increased odds of SFH 3–10. In Figure 4, post-estimation regression lines showing the odds of SFH 3–10 with higher ferritin and IL-12 are presented.

Model for CLAP and INTERGROWTH SFH >90th centile

By using the MFP algorithm, no variables emerged as being significantly associated with SFH >90th centile using either CLAP or INTERGROWTH standards (models not shown).

MFP linear regression models for hepcidin

Given the unexpected association found between higher hepcidin with an SFH <3rd centile, we explored associations of hepcidin with MINDI variables while controlling for GA (weeks) and SFH (centimeters) in a model shown in Table 5. We observed that hepcidin was inversely associated with SFH in centimeters, after adjusting for other variables, including GA. Moreover, nutrient indicators (higher intake of MNS, higher ferritin), a lower urinary pH, and inflammation (higher CRP and IL-17) were associated with higher hepcidin and explained 40.1% of its variability. No infections entered our bootstrap procedure for inclusion into MFP models.

Discussion

SFH is widely used in developing countries to screen for SGA with a reported specificity of ≥80% (1, 58, 59). However, the utility of SFH goes beyond the prediction of SGA, given its association with not only fetal weight but also amniotic fluid volume and GA (3, 19). Our goal had been to apply both CLAP and the new international INTERGROWTH standards for SFH (12) to our MINDI cohort. Based on CLAP standards, low SFH was detected in only 8% of our study population, whereas >50% of our study population had an SFH <10th centile based on the more recent international INTERGROWTH standards. A recent study assessing the prevalence of SGA (birthweight <10th centile) using the INTERGROWTH standards in low- and middle-income countries reported the highest world estimates of 34% for South Asia (60). In contrast, in our study, the prevalence of an SFH <3rd centile was higher and approached 40% in the Ngäbe-Buglé indigenous community in Panama. Previously, maternal infection/inflammation (61–63) and decreased plasma volume expansion or hypovolemia (38, 64) had been associated with both SGA infants and low amniotic fluid volume. Maternal malnutrition also had been associated with SGA (65). In the present study we report associations of maternal infections, inflammation, and nutrient deficiencies with SFH, which highlights the potential of SFH to assist in the identification of factors contributing to the etiology of high-risk pregnancies in resource-poor settings.
In our MINDI cohort, 4 novel findings emerged:

1) Haptoglobin was the main determinant of an SFH <10th centile (CLAP) and an SFH <3rd centile (INTERGROWTH), and haptoglobin was associated with indicators of inflammation (ferritin, IL-17, CRP) and indirect indicators of hypovolemia and malnutrition (lower urinary pH and higher intake of MNS).

2) In contrast, higher pulse pressure and TNF-α were associated with lower odds of an SFH <3rd centile (INTERGROWTH) and higher TNF-α also decreased the odds of an SFH <10th centile (CLAP).

3) Both wood smoke and Trichuris infection were associated with low SFH.

4) Inflammation biomarkers were associated with SFH; higher ferritin and IL-12 increased the odds of SFH 3–10 compared with SFH 10–90, whereas higher lymphocyte counts, higher IL-17 and higher MCP-1 were associated with decreased odds of SFH <3rd centile when compared with SFH 3–10.

These findings are highlighted in Figure 5.

Determinants of hepcidin provide insight to its association with SFH

Haptoglobin, a protein synthetized in the liver, is the main modulator of iron concentrations in response to elevated iron (66), and under inflammatory conditions an increase in haptoglobin inhibits intestinal iron absorption and the release of iron from recycling macrophages (67). Hepcidin was suppressed in a healthy pregnancy (68–71), which favors the supply of iron for augmented erythropoiesis and for fetal growth (72).

Furthermore, our MFP regression model for hepcidin showed independent associations of haptoglobin with ferritin, CRP, IL-17, urinary pH, and the intake of MNS, aligning with previous reports in the literature where haptoglobin was associated with ferritin in pregnant Gambian women (73); however, evidence of the association of haptoglobin with infection, inflammation, and malnutrition during pregnancy or with SFH has not been described.

Not unexpectedly, higher haptoglobin was associated with higher ferritin, as previously described (74). However, in the present study, the majority of these pregnant indigenous women had ferritin <20 μg/L,
an indicator of depleted iron stores (40), making it unlikely that hepcidin in these pregnant women was responding to elevated iron concentrations (75). We show that other factors, including inflammation, hypovolemia, and malnutrition, were associated with higher hepcidin in this marginalized community where co-existing infections, nutrient deficiencies, and inflammation were common.

**Inflammation.**

No association between hepcidin and CRP has been reported in healthy Eurasian (76), European (69), or African (73) pregnant women. However, during inflammation, hepcidin can increase in pregnant women even if iron deficiency is present (77). In our study, CRP was positively associated with hepcidin; thus, the higher hepcidin may reflect its association with this biomarker of inflammation. Moreover, among the cytokines we measured, IL-17 was the only one entering the hepcidin model. Although both IL-17 and hepcidin increase during infections (78), the association of hepcidin with IL-17 in our poly-infected pregnant women is novel and requires further investigation.

**Urinary pH.**

In this population of pregnant mothers with low plasma volumes we found a consistent association of hepcidin with lower urinary pH, another indicator of volemic status (51), suggesting that hemoconcentration, previously reported in this population (25), may contribute to higher hepcidin concentrations.

Urinary pH also reflects the serum acid–base state (49). Based on experimental studies, it has been proposed that metabolic acidosis may contribute to the elevation of hepcidin in clinical conditions (79), and it is known that fasting-induced metabolic acidosis with ketone body production is more frequent in the third trimester of pregnancy due to increased energy requirements (80). An acidic environment occurs in the presence of fasting (81), and therefore may be another condition that contributes to our observation of higher hepcidin in our population. In support of hepcidin being higher due to fasting, we observed an association of higher hepcidin with higher MNS intake, which may reflect an energy deficit. During our visits to the field, we noticed that mothers largely relied on MNS, sometimes as the sole source of nutrition. Our findings also provide evidence that nutritional...
supplementation programs in vulnerable populations are modest at best (82).

Collectively, these results confirm associations of hepcidin with several biomarkers of inflammation, hypovolemia, and nutritional status and highlight the possibility that hepcidin may be a potential marker of maternal–fetal well-being when infections, inflammation, and malnutrition co-exist.

Other predictors of low SFH
A second novel factor that emerged in our study was the association of decreased odds of both an SFH <10th centile from CLAP and an SFH <3rd centile from INTERGROWTH with higher TNF-α. We had previously reported that higher pulse pressure was associated with higher TNF-α and that pulse pressure <30 mm Hg, an indicator of low peripheral perfusion, was associated with lower SFH z scores (25). Although TNF-α concentrations may also reflect fetal antimicrobial defense against infection (83), TNF-α is known to increase during normal pregnancy (84) and has also been recognized as a critical factor for placental development (85). TNF-α has been shown to be high in SGA associated with preeclampsia, but not with idiopathic SGA (86), and in intrauterine growth retardation (IUGR) associated with placental insufficiency but not in those with IUGR with normal placental perfusion (87). Given that the increase in TNF-α in pregnancies complicated with preeclampsia is probably a consequence of placental hypoxia (88), our results support the possible role of this cytokine in the compensatory increase in uterine perfusion under low plasma volume and low pulse pressure conditions as an explanation of its association with decreased odds of an SFH <3rd centile.

Nutrition and SFH
SFH has been previously reported as an indicator of maternal nutritional status. In a Malawian study of moderate-malnutrition pregnancies, SFH was lower in adolescent compared with adult females (89). Similarly, we found that an older maternal age decreased the odds of SFH 3–10 and that higher BMI decreased the odds of an SFH <3rd centile. In our study population, diet questionnaires showed the low intake of animal foods, the main source of vitamin B-12 (90), which, together with low concentrations of the vitamin and of RBP, an indicator

![FIGURE 4](https://example.com/figure4.png)

**FIGURE 4** Fractional polynomial logistic regression lines with 95% CIs (gray areas) for associations of ferritin (μg/L) (A) and IL-12 (pg/mL) (B) with SFH 3–10 compared with SFH 10–90 using INTERGROWTH-21 standards, adjusted for all covariates in the model. SFH 3–10, symphysis–fundal height ≥3rd to <10th centiles; SFH, 10–90, symphysis–fundal height ≥10th to ≤90th centiles.

| Log hepcidin          | Coefficient ± SE | P     | 95% CI            | β     | Overall model |
|-----------------------|------------------|-------|-------------------|-------|---------------|
| t GA (wk)             | 0.01 ± 0.003     | 0.010 | 0.002, 0.016      | 0.28  | P < 0.0001, adjusted |
| t SFH (cm)            | −0.03 ± 0.01     | 0.004 | −0.05, −0.01      | −0.32 | R² = 0.401    |
| t MNS intake (tbsp/d) | 0.05 ± 0.02      | 0.035 | 0.004, 0.10       | 0.14  |               |
| t MAP, mmHg           | 0.001 ± 0.005    | 0.783 | −0.01, 0.01       | 0.02  |               |
| t CRP, mg/L           | 0.03 ± 0.01      | <0.0001 | 0.01, 0.05      | 0.23  |               |
| t IL-17, pg/mL        | 0.01 ± 0.0005    | 0.012 | 0.003, 0.02       | 0.16  |               |
| t Urinary pH          | −0.12 ± 0.04     | 0.008 | −0.21, −0.03      | −0.17 |               |
| t Ferritin, μg/L      | 2.14 ± 0.05      | <0.0001 | 2.05, 2.23      | 0.40  |               |
| Constant              | 2.14 ± 0.05      | <0.0001 | 2.05, 2.23      |       |               |

1Variables that entered ≥500 repetitions but were taken out by the MFP process: parity, coffee intake (cups/d), MAP (mm Hg), RBC count, number of monocytes and eosinophils, TNF-α (pg/mL), presence of scabies, scores of Lactobacillus, and vitamin B-12 (pmol/L). The MFP process provided the following equations for transforming covariates (t): t GA (wk) = X² − 26.13282964, where X = GA/10; t SFH (cm) = SFH − 26.8606066; t MNS (tbsp/d) = MNS − 1.375757576; t MAP (mm Hg) = MAP − 75.11313162; t CRP (mg/L) = CRP − 4.92727271; t IL-17 (pg/mL) = IL-17 − 6.413284447; t Urinary pH = pH − 6.415151515; t Ferritin (μg/L) = ln(X) − 1.833487176, where X = ferritin/100. MFP linear regression model for hepcidin.

Current Developments in Nutrition
of protein status (47), strongly support our observation of protein malnutrition in these indigenous mothers.

Even though the need for iron to promote fetal and future infant development is well known (91), the effect of iron deficiency on fetal growth is somewhat controversial. An older meta-analysis on the effect of iron supplementation during pregnancy commissioned by the WHO found that iron supplementation increased birth weight by 100 g at most (92). This meta-analysis also acknowledged limitations, as only 1 study provided solid evidence of a positive effect of iron supplementation on birth weight and that both high and low hemoglobin concentrations were associated with smaller infants (92). However, given that maternal iron deficiency is often associated with impaired fetal growth and development (93), we might have expected to find an association of higher SFH with iron supplementation, or an association of an SFH <10th centile with lower iron status. However, iron supplementation did not enter our models for low SFH, whereas higher ferritin increased the odds of SFH 3–10 compared with SFH 10–90. It is likely that ferritin in our population is influenced by inflammation and may not only reflect maternal iron status.

There is evidence that elevated ferritin is associated with impaired fetal growth. Ferritin concentrations >48 μg/L have been proposed as a predictor of IUGR, whereas concentrations <22 μg/L would be indicative of constitutional SGA fetuses (94), an approach that was not possible to apply in our study because most women were iron deficient and only 8% reached ferritin values >48 μg/L. Our findings do support current Panamanian guidelines for iron supplementation during pregnancy, which preclude the use of iron in women with infections (95) due to the risk of exacerbation of some infections (96).

**SFH 3–10 contrasts with SFH ≤3rd centile**

We were intrigued by the observation that an SFH <3rd centile and SFH 3–10 had different determinants when compared with SFH 10–90. Whereas the odds of an SFH <3rd centile were increased by hepcidin and decreased by higher BMI and TNF-α, higher ferritin and IL-12 distinguished SFH 3–10 from normal SFH 10–90. Moreover, a higher pulse pressure and inflammation indicators (higher lymphocytes, IL-17, and MCP-1) distinguished SFH 3–10 from SFH <3rd centile, suggesting that intrauterine perfusion and/or inflammation underscored differences and a possible different etiology of impaired intrauterine growth between these 2 groups.

In our model for SFH 3–10 compared with normal SFH (10–90), higher ferritin and IL-12 emerged as increasing the odds of SFH 3–10. It has been reported that the absence of a decline in ferritin concentrations as pregnancy progresses is associated with increased odds of chorioamnionitis (97). Also, IL-12 has been proposed as a biomarker of chorioamnionitis caused by *Ureaplasma urealyticum* (98), a common cause of urogenital infection (99). Furthermore, the possibility of subclinical chorioamnionitis is supported by our finding that cytokines increased the odds of SFH 3–10 when compared with an SFH <3rd centile. Three other biomarkers entering this model—lymphocyte counts (100, 101), IL-17 (102), and MCP-1 (103)—have all been linked with intra-amniotic infection. This subclinical condition may precede chorioamnionitis, which usually develops from urogenital infections, particularly bacteria associated with urinary infection (104) and bacterial vaginosis (105), which were present in a large majority (64% and 61%, respectively) in our study population.

The association of higher ferritin increasing the odds of SFH 3–10 compared with SFH 10–90 compared with normal SFH continues to support the inflammatory state associated with SFH 3–10. Higher ferritin has been suggested as a marker of infection in women with preterm rupture of membranes at <32 weeks of gestation (106). Moreover, maternal iron status indicated by higher ferritin at the beginning of pregnancy has been associated with better pregnancy outcomes, including higher birth weight;
however, higher ferritin at the end of pregnancy has been associated with preterm birth in women from Canada (107). Further exploration of ferritin as a biomarker of impaired fetal growth in marginalized communities is warranted based on our findings, with accompanying assessment of both iron and inflammatory parameters.

We also found it intriguing that in these women who were experiencing multiple bacterial, protozoan, and nematode infections, a lower protein status may have contributed to more women having an SFH <3rd centile as compared with those with SFH 3–10. Protein deficiency is known to impair the inflammatory response (108). There is experimental evidence of decreased IL-4 under maternal protein deprivation and during intestinal nematode infections (109). Others have reported that both T-helper (Th) 1 and Th-2 cytokines are negatively correlated with BMI in malnourished, noninfected, nonpregnant individuals (110) and it has also been described that Th-1 cytokines including IL-12 are lower in malnourished children (111). We suggest that the higher prevalence of protein deficiency in the <3rd-centile group may modulate immune responses, as SFH centile for GA was also lower in these protein-deficient women. In our study with poly-infected pregnant women, we also found lower eosinophils, basophils, and IL-4 but higher IL-10 and IL-13 in protein-deficient women, highlighting the complex interaction of protein malnutrition and immunity during pregnancy under MINDI conditions.

Other factors associated with low SFH

Infections.

Among the range of infections present in our population, only the presence of Trichuris was associated with increased odds of an SFH <3rd centile. Of note, in all women with Trichuris infection, hookworm coinfection was present. A possible explanation for the association of these nematodes with an SFH <3rd centile could be blood loss due to both hookworm (112) and Trichuris infection (113) leading to anemia. However, none of the RBC indices were associated with low SFH. Chronic Trichuris infections can experimentally elicit a persistent Th-1 immune response (114), suggesting that the associations of Trichuris with an SFH <3rd centile may be linked to inflammation.

Wood smoke.

In Guatemala, it was found that women cooking with open fires had infants with lower birth weights than those cooking with chimney stoves or those cooking with electricity or gas (115). Increased environmental carbon monoxide leading to the formation of carboxyhemoglobin is considered to be the common mechanism by which cigarette smoking contributes to low birth weights (115). Consistent with this, our study found that more hours of exposure per day to wood smoke was associated with the lowest SFHs detected by the CLAP <10th centile. Moreover, we had previously shown that wood smoke was associated with elevated CRP in this population (24). Given the known association of smoking with low birth weight (116), and the specificity of the CLAP standards for the detection of SGA, our findings highlight the need to target wood-smoke exposure as part of public health policies to decrease inflammation and improve pregnancy outcomes.

Conclusions

This study identified, for the first time, determinants of low SFH in the context of multiple infections, nutrient deficiencies, and inflammation in a marginalized community of pregnant indigenous women. Of interest, our study shows that hepcidin is associated with low SFH in the presence of malnutrition, inflammation, and with a nematode infection and also that INTERGROWTH standards provided the rare opportunity to study associations of MINDI with women having all ranges of SFH. We provide evidence that a low SFH in a MINDI context should alert clinicians to the possibility of inadequate plasma volume expansion, subclinical inflammation, and maternal malnutrition. Public health interventions leading to dietary improvements and increasing our understanding of the complexity of the inflammatory response associated with multiple infections may be important if we are to improve maternal and fetal health. The use of low SFH as a screening tool in remote settings for the identification of high-risk pregnancies is a first step.

Acknowledgments

We thank the “Virgen del Camino” Foundation, the traditional midwives and health care providers serving the Ngäbe-Buglé community for helping in recruitment and data collection, as well as laboratory technicians of the “Hospital General del Oriente Chiricano” in San Felix, Chiriqui province, Panama, for their collaboration in laboratory analyses. We also recognize the contribution of registered nurse DR and local nurses for providing clinical follow-up for pregnant women who needed treatment. The authors’ responsibilities were as follows—DG-F, MES, and KKG: designed the research and wrote the manuscript; EdCP, DR, and OTS: facilitated participation of indigenous communities in this study; DG-F, DR, EdCP, LMS, and EM: conducted either field or laboratory-based analyses; EN and VS: measured hepcidin and serum iron in their laboratory; DG-F: analyzed data and performed statistical analysis; EM and OTS: provided institutional support; DG-F, EN, MES, and KKG: had primary responsibility for final content; and all authors: read and approved the final manuscript.

References

1. Goto E. Prediction of low birthweight and small for gestational age from symphysis-fundal height mainly in developing countries: a meta-analysis. J Epidemiol Community Health 2013;67(12):999–1005.
2. Engstrom JL, Sittler CP. Fundal height measurement. Part 1—techniques for measuring fundal height. J Nurse Midwifery 1999;38(1):5–16.
3. Freire DM, Cecatti JG, Paiva CS. Is fundal height able to diagnose amniotic fluid volume deviations? Rev Bras Ginecol Obstet 2013;35(2):49–54, Portuguese.
4. Wanyonyi SZ, Mutiso SK. Monitoring fetal growth in settings with limited ultrasound access. Best Pract Res Clin Obstet Gynaecol 2018;49:29–36.
5. Blue NR, Beddow ME, Savabi M, Katukuri VR, Mozurkewich EL, Chao CR. A comparison of methods for the diagnosis of fetal growth restriction between the Royal College of Obstetricians and Gynaecologists and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;131(5):835–41.
6. Unterscheider J, O’Donoghue K, Malone FD. Guidelines on fetal growth restriction: a comparison of recent national publications. Am J Perinatol 2015;32(4):307–16.
7. Fescina RH, De Mucio B, Martínez G, Alemán A, Sosa C, Mainero L, Rubino M. Monitoring fetal growth: self-instruction manual [Internet]. Montevideo (Uruguay): Pan American Health Organization (PAHO),
Latin American Center for Perinatology/Women & Reproductive Health (CLAP/WR); 2011 [cited 2017 Jan 7]. Available from: http://www.paho.org/clap/index.php?option=com_docman&task=doc_details&gid=241&Itemid=.

8. Fescina RH, Quevedo C, Martell M, Nieto F, Schwarcz R. Fundal height as a method of predicting fetal growth. Boletín Oficina Sanit Panam 1984;96(5):377–86. In Spanish.

9. WHO. WHO recommendations on antenatal care for a positive pregnancy experience [Internet]. Geneva (Switzerland): World Health Organization; 2016 [cited 2020 Feb 19]. Available from: https://www.who.int/reproductivehealth/publications/transition/transition-matr_perinatal_health_part-anc-positive-pregnancy-experience/en/.

10. Robert Peter J, Ho JJ, Valliapan J, Sivasangari S. Symphysis fundal height (SFH) measurement in pregnancy for detecting abnormal fetal growth. Cochrane Database Syst Rev 2019;5:CD008136.

11. Pay A, Froen JF, Staff AC, Jacobsson B, Giessing HK. Prediction of small-for-gestational-age status by symphysis-fundus height: a registry-based population cohort study. BJOG 2016;123(7):1167–73.

12. Papageorghiou AT, Ohuma EO, Gravett MG, Hirst J, da Silveira MF, Lambert A, Carvalho M, Jaffer Y, Allman DG, Noble JA, et al. International standards for symphysis-fundal height based on serial measurements from the Fetal Growth Longitudinal Study of the INTERGROWTH-21st project: prospective cohort study in eight countries. BMJ 2016;355:i5662.

13. Unger H, Thriemer K, Levy B, Tinto H, Traoré M, Valea I, Tagbor H, Antwi G, Gbekor P, Nambozzi M, et al. The assessment of gestational age: a comparison of different methods from a malaria pregnancy cohort in sub-Saharan Africa. BMC Pregnancy Childbirth 2019;19(1):12.

14. Malaba TR, Newell M-L, Madllala H, Perez A, Gray C, Myer L. Methods of gestational age assessment influence the observed association between antiretroviral therapy exposure, preterm delivery, and small-for-gestational-age infants: a prospective study in Cape Town, South Africa. Ann Epidemiol 2018;28(12):893–900.

15. Traisathit P, Le Cœur S, Mary JY, Kanjanasing A, Lamlertkittikul S, Herráiz JA, Scott ME, Koski KG. Identification of high-risk pregnancies in a remote setting for gestational age babies: development and validation in two general population cohorts. BJM 2015;351:h5948.

16. Malaba TR, Newell M-L, Madllala H, Perez A, Gray C, Myer L. Methods of gestational age assessment influence the observed association between antiretroviral therapy exposure, preterm delivery, and small-for-gestational-age infants: a prospective study in Cape Town, South Africa. Ann Epidemiol 2018;28(12):893–900.

17. Malik AY, Foster C. The revised Declaration of Helsinki: cosmetic or real change? JR Soc Med 2016;109(5):184–9.

18. INEC. Live births and fetal deaths: 2010. Panama: National Institute of Statistics and Census; 2018. [cited 2019 Jan 3]. Available from: https://www.inec.go.b petablehealth/atal_health/anc-positive-pregnancy-experience/en/.

19. Panamanian Ministry of Health. Analysis of health situation. Panama 2015. Panama: Panamanian Ministry of Health; 2015. In Spanish [cited 2016 Nov 14] [Internet]. Available from: http://www.minsa.go.b/p/sites/default/files/publicaciones/asis_2015.pdf.

20. Fescina R. Weight gain during pregnancy. Calculation method when pre-gestational weight is unknown. Boletín Oficina Sanit Panam 1983;95(2):156–62. In Spanish.

21. Fescina RH, De Mucio B, Diaz Rossello JL, Martinez G, Serruya S, Durán P. Sexual and reproductive health: guidelines for the continuum of care for women and newborns focused on primary health care [Internet]. Montevideo (Uruguay): Latin American Center of Perinatology, Women and Reproductive Health (CLAP/SR-OFSMOS); 2011. In Spanish [cited 2019 Oct 2]. Available from: http://www.paho.org/clap/index.php?option=com_docman&task=download&category_slug=aguas-de-mujer-reproductiva&alias=416-salud-sexual-y-re productiva-guias-para-el-continuo-de-atencion-de-la-mujer-y-el-recien-nacido-focalizadas-en-3-ed-6&Itemid=219&lang=es.

22. Macdonald-Wallis C, Silverwood RJ, de Stavola Bl, Inskip H, Cooper C, Godfrey KM, Crozier S, Fraser A, Nelson SM, Lawlor DA, et al. Antenatal blood pressure for prediction of pre-eclampsia, preterm birth, and small for gestational age babies: development and validation in two general population cohorts. BMJ 2015;351:h5948.

23. Kuc S, Koster MP, Franx A, Schielen PC, Visser GH. Maternal characteristics, mean arterial pressure and serum markers in early prediction of preeclampsia. PLoS One 2013;8(5):e63546.

24. WHEC. Normal values in pregnancy [Internet]. Springfield (MA): The Women’s Health and Education Organization, Inc; 2009 [cited 2016 Aug 27]. Available from: http://www.womenshealthsection.com/content/obs/ob cookbooks.php.

25. Klabunde RE. Vascular function. In: Taylor C, editor. Cardiovascular physiology concepts. 2nd ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2012. p. 97–8.

26. Hauser RG, Kwon RI, Ryder A, Cheng C, Charifa A, Tormey C. Blood pressure for prediction of pre-eclampsia, preterm birth, and small for gestational age babies: development and validation in two general population cohorts. BMJ 2015;351:h5948.

27. Stiegitz E, Huang J. Plasmapheresis technique. [Internet]. New York: Medscape; 2018 [cited 2019 Aug 6]. Available from: https://emedicine.medscape.com/article/1895577-technique.

28. de Haas S, Ghoossein-Doha C, van Kuijk SM, van Drongelen J, Spaanderman ME. Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2017;49(2):177–87.
39. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991;29(2):297–301.

40. WHO: CDC. Assessing the iron status of populations. Health topics: nutrition [Internet]. WHO, CDC. 2007 [cited 2019 Oct 3]. Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjJ9f2DrsmwAhWoiOA5HAevChAQFjACegOBw&url=https%3A%2F%2Fwww.who.int%2FNutrition%2Fp ublications%2Fmicronutrients%2Fanaemia_iron_deficiency%2F9789241596107.pdf&usg=AOvVaw33wDDlHitq4A8bOuwG3mT.

41. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol 2009;114(6):1326–31.

42. Gundersen TE, Lundanes E, Blomhoff R. Quantitative high-performance liquid chromatographic determination of retinoids in human serum using online solid-phase extraction and column switching. Determination of 9-cis-retinoic acid, 13-cis-retinoic acid, all-trans-retinoic acid, 4-oxo-all-trans-retinoic acid and 4-oxo-13-cis-retinoic acid. J Chromatogr B Analyt Technol Biomed Life Sci 1997;691(1):43–58.

43. de Bonten R. Conclusions of a WHO Technical Consultation on folate and vitamin B12 deficiencies. Food Nutr Bull 2008;29(2 Suppl):S238–44.

44. Balvers MG, Brouwer-Brolsma EM, Endenburg S, de Groot LC, Kok FJ, Gunnewiek JK. Recommended intakes of vitamin D to optimize health, associated circulating 25-hydroxyvitamin D concentrations, and dosing regimens to treat deficiency: workshop report and overview of current literature. J Nutr Sci 2015;4:e23.

45. Wiseman EM, Bar-El Dadon S, Reifen R. The vicious cycle of vitamin A restriction and intra-uterine growth restriction: guidelines for clinical practice. J Obstet Gynaecol Can 2014;36(7):739–51.

46. Mulone S, Marin S, Bonometto P. Role of visceral proteins in detecting vitamin B12 deficiencies. Food Nutr Bull 2008;29(2 Suppl):S238–44.

47. Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders. Blood 2016;127(23):2809–13.

48. Kim BJ, Romero M, Lee S, Park CW, Shin Park J, Jun JK, Yoon BH. Clinical significance of oligohydramnios in patients with preterm labor and intact membranes. J Perinat Med 2011;39(2):131–6.

49. Lagarri RR, Khan MS, Azziz Z, Blaauw A, De Jonge M, Meuwissen H. Iron metabolism and its outcome. Am J Perinatol 2016;33(14):1337–56.

50. Weckman AM, Ngaï M, Wright J, McDonald CR, Kain KC. The impact of infection in pregnancy on placental vascular development and adverse birth outcomes. Front Microbiol 2019;10:1924.

51. Kalagiri RR, Carder T, Choudhury S, Vora N, Ballard AR, Govande V, Dvreer N, Beerman MR, Uddin MN. Inflammation in complicated pregnancy and its outcome. Am J Perinatol 2016;33(14):1337–56.

52. Li J, Romero M, Lee S, Park CW, Shin Park J, Jun JK, Yoon BH. Clinical significance of oligohydramnios in patients with preterm labor and intact membranes. J Perinat Med 2011;39(2):131–6.

53. Kim BJ, Romero M, Lee S, Park CW, Shin Park J, Jun JK, Yoon BH. Clinical significance of oligohydramnios in patients with preterm labor and intact membranes. J Perinat Med 2011;39(2):131–6.

54. Balvers MG, Brouwer-Brolsma EM, Endenburg S, de Groot LC, Kok FJ, Gunnewiek JK. Recommended intakes of vitamin D to optimize health, associated circulating 25-hydroxyvitamin D concentrations, and dosing regimens to treat deficiency: workshop report and overview of current literature. J Nutr Sci 2015;4:e23.

55. Hosmer DW, Lemeshow S, Sturdivant RX. Model-building strategies and assessment of predictors selected for epidemiologic risk models using automated variable selection. Int J Stat Appl 2017;7(5):239–49.

56. Vayssiere C, Sentilhes L, Ego A, Bernard C, Cambourieu D, Flamant C, Papathakis PC, Singh LN, Manary MJ. How maternal malnutrition affects linear growth and development in the offspring. Mol Cell Endocrinol 2016;435:40–7.

57. Little RJA. A test of missing completely at random for multivariate data with applications. Biometrika 1988;75(1):227–40.

58. Pay AS, Wiik J, Backe B, Jacobsson B, Strandell A, Klovning A. Sympyaxis-fundus height measurement to predict small-for-gestational-age status at birth: a systematic review. BMC Pregnancy Childbirth 2015;15:22.
2016. Guillen R, Roldan M, Marquez M, et al. The role of maternal smoking in preterm birth: an updated systematic review of observational studies. Best Practice & Research Clinical Obstetrics & Gynaecology 2016;30(6):735–48.

2017. Abraham M, Alramadhan S, Iniguez C, Duijts L, Jaddoe VW, Den Dekker JH, et al. Iron status in pregnancy and adverse perinatal outcomes. Paediatr Perinat Epidemiol 2017;31(3):275–85.

2018. Taylor KE, Wood L, Chalmers A, et al. Iron deficiency anemia and low birth weight: a systematic review and meta-analysis. Obstet Gynecol 2018;132(5):1019–30.

2019. Abraham M, Alramadhan S, Iniguez C, Duijts L, Jaddoe VW, Den Dekker JH, et al. Iron status in pregnancy and adverse perinatal outcomes. Paediatr Perinat Epidemiol 2017;31(3):275–85.

2020. Abraham M, Alramadhan S, Iniguez C, Duijts L, Jaddoe VW, Den Dekker JH, et al. Iron status in pregnancy and adverse perinatal outcomes. Paediatr Perinat Epidemiol 2017;31(3):275–85.